$1.90
-0.34 (-15.18%)
Open$1.92
Previous Close$2.24
Day High$2.05
Day Low$1.81
52W High$2.57
52W Low$1.15
Volume—
Avg Volume511.1K
Market Cap83.73M
P/E Ratio—
EPS$-1.05
SectorBiotechnology
Analyst Ratings
Strong Buy
9 analysts
Price Target
+1,614.2% upside
Current
$1.90
$1.90
Target
$32.57
$32.57
$26.16
$32.57 avg
$50.99
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 10.28M | 9.86M | 9.80M |
| Net Income | -1,154,434 | -865,846 | -1,110,362 |
| Profit Margin | -11.2% | -8.8% | -11.3% |
| EBITDA | -1,433,621 | -1,413,990 | -1,277,421 |
| Free Cash Flow | -904,387 | -870,700 | -861,997 |
| Rev Growth | +11.1% | +6.2% | +2.7% |
| Debt/Equity | 0.32 | 0.28 | 0.29 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $251.64 | -1.05% | 118.2 | 429.58B |
| AMGN | Amgen Inc | $362.12 | +0.44% | 24.8 | 193.10B |
| GILD | Gilead Sciences Inc | $126.34 | +0.01% | 17.1 | 157.21B |
| VRTX | Vertex Pharmaceuticals Inc | $496.73 | -0.58% | 28.1 | 121.87B |
| REGN | Regeneron Pharmaceuticals | $623.54 | -1.31% | 15.0 | 66.35B |
| ALNY | Alnylam Pharmaceuticals Inc | $301.03 | +2.56% | 69.3 | 39.97B |